Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryReappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesManagement of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelinesIntegrin-based therapeutics: biological basis, clinical use and new drugsPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsManaging Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial FibrillationPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionRole of abciximab in the treatment of coronary artery diseaseStent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapyAspirin before reperfusion blunts the infarct size limiting effect of atorvastatinClopidogrel: an updated and comprehensive reviewAre patients with non-ST elevation myocardial infarction undertreated?Contemporary issues in clopidogrel therapy: new evidence shaping clinical practicePharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Acute coronary syndromes: diagnosis and management, part ITirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Tirofiban for myocardial infarction.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort studyThe Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus IntracoronaryGlycoprotein IIb/IIIa inhibitors use and outcome after percutaneous coronary intervention for non-ST elevation myocardial infarction.Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.Non ST-elevation acute coronary syndrome.Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Percutaneous treatment in acute coronary syndromes.Current antiplatelet treatment strategy in patients with diabetes mellitus.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesIncreased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyAntiplatelet treatment for coronary heart disease.
P2860
Q22241786-652C4A00-F8E1-45B3-A5FF-09D37C4E8775Q22242057-FE46F7A0-D571-474A-8377-53B8A261D5C4Q24202522-6F648B29-E94B-4CA0-A77A-4BBCEAC9B67DQ24202999-43688F74-34DB-43AE-AEAD-DFE6EF6E0236Q24235385-FE7432E2-FC73-4058-A929-FE6DFD0BFFC1Q24653318-09B261BB-9B14-4872-ACB8-A871C5B8A3AEQ26773026-2814990B-3056-4975-9C51-56508874B2F3Q26862694-7193C68D-C93D-439A-9A36-EDB8790DD2CFQ28080247-AA44C50D-D9EC-4C93-8D58-01C1FC1244DBQ28191096-14B74997-A9BC-4E9B-A880-A8677D8F8B13Q28200177-6449C388-E7DB-4550-A9C5-46CF5E8EDBCCQ28218066-8A47C89D-F6BF-49A6-B420-2482B49F86FAQ28218700-01FC355C-1A8C-4E27-AC27-BBCA662CE8E5Q28219411-19D9B3C1-F98F-446A-BDFA-B51FC024E1F3Q28219991-B8D46EAC-F840-414A-B098-43F1AD4580FBQ28221366-FE3AF6E3-2CEC-4909-AA60-0042D1B7F35BQ30238719-214EB6B9-951C-412A-AC56-A532CD5B84DCQ30402038-39D66D55-3546-4A21-AE15-6FAFCCEA3E4FQ30438893-D403CE02-0F2D-4110-B2FA-81390A33F377Q30490718-9407C00D-81F9-4CA5-8574-F65B7600C53BQ33386229-A7BB1A27-0619-4E97-8CD9-392294B6BDC1Q33387192-EDE0D6CC-41C7-4767-BD58-8E72A877085BQ33388527-6565CE7F-8FD5-4709-BD43-E86BFDB1C6E5Q33390176-05442E9E-82CB-4A18-A15C-C44EDFE2D15AQ33391341-FCE450C3-14FC-48FB-83EE-8D7E081667C0Q33406801-3EEAA4D2-E772-422D-95B6-4D411A2CC943Q33434702-D8E39DBF-04BC-43D8-824C-67684A96FDC9Q33527547-91FF2A95-ADB8-437D-83FF-1CCB8C372889Q33572281-49370E8F-5961-4230-8570-FABCFD92926DQ33666662-A4587425-8EF0-4AC4-A8F8-57F6362EB187Q33715389-0A8DB5EB-6691-4C73-97DC-9C7063FA7DFDQ33846765-F4CD15BF-CA44-4ECB-AE75-4BBCE9843E99Q33876187-F822913B-4186-4A73-B418-0875117F87B5Q33934090-654B5F38-4CCF-4F45-8B86-A25E8171A793Q34716730-F5FD914A-07F5-4D3A-95B4-92ED0350120DQ35510430-3446DC61-CD69-4378-8503-5EEAD079BE00Q35544048-9B4D479C-8898-4E32-8900-823F78041EF7Q35752619-9D5BC2E5-4F14-4198-9F14-A2F42F673887Q35755253-D623FF29-6EC5-4ACA-B12D-5B125E915317Q35773210-D803DEC7-8AB3-4C2F-9683-9FDF1083986E
P2860
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Abciximab in patients with acu ...... ISAR-REACT 2 randomized trial.
@en
type
label
Abciximab in patients with acu ...... ISAR-REACT 2 randomized trial.
@en
prefLabel
Abciximab in patients with acu ...... ISAR-REACT 2 randomized trial.
@en
P2093
P50
P1476
Abciximab in patients with acu ...... ISAR-REACT 2 randomized trial.
@en
P2093
Franz Dotzer
Franz-Josef Neumann
Helmut Schühlen
Hildegard Bollwein
Intracoronary Stenting and Ant ...... R-REACT 2) Trial Investigators
Isolde Graf
Josef Dirschinger
Jurriën ten Berg
Jürgen Pache
Maryam Ibrahim
P304
P356
10.1001/JAMA.295.13.JOC60034
P407
P577
2006-03-13T00:00:00Z